Skip to main content Skip to choc.org search

All Clinical Trials:

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects > 1 and < 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Clinical Trial Protocol # JNJ-54767414 | Adolescents and Young Adults, Leukemia/Lymphom, Recurrent/Refractory Cancer | Contact (714) 509-8646

TINI, Total Therapy For Infants with Acute Lymphoblastic Leukemia (ALL) I

Clinical Trial Protocol # TINI | Leukemia | Contact (714) 509-8646

ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after

Clinical Trial Protocol # AHOD1721 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS

Clinical Trial Protocol # ADVL1711 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors

Clinical Trial Protocol # ADVL1614 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Oncology Clinical Trial: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant or Intolerant to Imatinib

Clinical Trial Protocol # 90325 | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer, oncology | Contact (714) 509-8646

Oncology Clinical Trial: Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Clinical Trial | Supportive Care | Contact (714) 509-8646

Oncology Clinical Trial: Treatment for Advanced B-Cell Lymphoma

Clinical Trial | Adolescents and Young Adults, Leukemia/Lymphoma, Recurrent/Refractory Cancer | Contact (714) 509-8646

Oncology Clinical Trial: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1312 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Oncology Clinical Trial: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Clinical Trial Protocol # ADVL1522 | Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Long Live Childhood

Facebook Twitter Pinterest Instagram Snapchat LinkedIn YouTube